1. Home
  2. MTLS vs SPRY Comparison

MTLS vs SPRY Comparison

Compare MTLS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$7.84

Market Cap

431.6M

Sector

Technology

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$4.48

Market Cap

473.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTLS
SPRY
Founded
1990
2015
Country
Belgium
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
431.6M
473.4M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
MTLS
SPRY
Price
$7.84
$4.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$40.00
AVG Volume (30 Days)
162.4K
1.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$6.38
$87.40
Revenue Next Year
$6.45
$81.64
P/E Ratio
$61.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.78
$4.07
52 Week High
$7.97
$13.15

Technical Indicators

Market Signals
Indicator
MTLS
SPRY
Relative Strength Index (RSI) 68.80 36.03
Support Level $6.37 N/A
Resistance Level N/A $8.61
Average True Range (ATR) 0.23 0.25
MACD 0.03 -0.06
Stochastic Oscillator 84.54 22.80

Price Performance

Historical Comparison
MTLS
SPRY

About MTLS Materialise NV

Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: